MILOZYME was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Over the decades, we have established ourselves as a leading player in the discovery of new molecules both NCEs (New Chemical Entity) and NBEs (New Biological Entity). We have several molecules in various stages of pre-clinical and clinical development and are primarily focused in the areas of Oncology, Respiratory and Dermatology.
Our branded generics business has a significant presence in markets across emerging economies including India.
The generics business services the requirements of developed markets like US and Western Europe. Our API business sells products in over 20 countries including the US, various countries in the EU, South America and India.
With 10 manufacturing facilities and 5 R&D centers dedicated to the goal of enriching lives across the globe we believe that the real force behind our continued successes are dedicated employees from across 50 nationalities, committed to creating 'A new way for a new world'.